RCS - Ondine Biomedical - Expanding Steriwave Use Across Vancouver Island

Ondine BiomedicalAnnouncement

27/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260127:nRSa4433Qa&default-theme=true

RNS Number : 4433Q  Ondine Biomedical Inc.  27 January 2026

27 January 2026

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Expanding Steriwave Use Across Vancouver Island

Island Health's New Regional Powerhouse, Cowichan District Hospital, Adopts
Steriwave to Lead Vancouver Island in Surgical Innovation

Ondine Biomedical Inc. (AIM: OBI) today announced that Cowichan District
Hospital, a facility within the Island Health Authority in British Columbia,
is adopting Steriwave® nasal photodisinfection as a standard component of
pre-surgical protocols for its orthopedic patients to protect them from the
growing risk of multidrug resistance.

The adoption of this cutting-edge technology comes as Cowichan Hospital
undergoes a massive transformation and prepares for the historic opening of
its new CAD$1.4 billion, 607,000-square-foot campus-three times the size of
its current facility. The expansion nearly doubles the number of operating
rooms, from four to seven, signaling Cowichan's emergence as a premier
destination for complex orthopedic surgeries and joint replacements.

By integrating Ondine Biomedical's Steriwave system, Cowichan Hospital is
providing its orthopedic patients with a "gold standard" of infection
prevention. Steriwave uses a non-invasive, five-minute light-activated process
to eliminate pathogens in the nose-a primary reservoir for bacteria that cause
surgical site infections (SSIs). Unlike traditional antibiotics, Steriwave is
effective immediately and does not contribute to the "superbug" crisis. For a
hospital rapidly scaling surgical capacity to meet the needs of a growing
population, this innovation is a critical safeguard. Adopters of the
technology, such as the Mid Yorkshire Teaching NHS Trust in the UK, have seen
hip and knee SSIs plummet by as much as 71%.

A Future-Forward Medical Hub

Carolyn Cross, CEO of Ondine Biomedical Inc., commented:

"Cowichan is migrating from community hospital to a regional leader in
innovation and we are proud to be part of that evolution. As this facility
triples in size to become one of the most significant medical centers in
British Columbia, the clinical team is ensuring that patient safety keeps pace
with that growth. We are honored to support the Cowichan Valley in helping to
protect patients and families from the growing threat of drug-resistant
infections with our rapid and painless photodisinfection procedure."

The adoption of Steriwave at the new Quw'utsun Hulitun-ew't-hw facility
underscores the hospital's commitment to "future-proofing" healthcare in the
region, as it expands its emergency department to over 36 treatment spaces,
becomes B.C.'s first fully electric and "Salmon-Safe" certified hospital, and
increases the number of surgical procedure rooms by 200% to help reduce wait
times for Vancouver Island residents.

About Cowichan Hospital & Island Health

Cowichan Hospital, operated by Island Health, is the primary acute care
facility for the Cowichan Valley. With the completion of its new regional
campus in 2026/2027, it will stand as one of the most technologically advanced
hospitals in Canada, serving as a critical hub for surgical excellence,
emergency care, and Indigenous health services.

About Steriwave®

Steriwave is a painless, two-step photodisinfection process. A light-activated
agent is applied to the nostrils and then activated by a safe red light,
triggering an oxidative burst that destroys bacteria, viruses, and fungi in
minutes. It is a proven, non-antibiotic solution to preventing infections
before they start.

 

Enquiries:

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave®. In the US, it has been granted Qualified
Infectious Disease Product designation and Fast Track status by the FDA and is
currently undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFLLLFIRFIR



            Copyright 2019 Regulatory News Service, all rights reserved